{
    "nct_id": "NCT04514159",
    "official_title": "A Phase 1b Study of ZN-c5 in Combination With Abemaciclib in Patients With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer",
    "inclusion_criteria": "* Age ≥ 18 years of age\n* Women can be peri- or postmenopausal, as defined by at least one of the following:\n\n  * Age ≥ 60 years;\n  * Age < 60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and follicle-stimulating hormone (FSH) level within the laboratory's reference range for postmenopausal females;\n  * Documented bilateral oophorectomy;\n  * Must receive a gonadotrophin-releasing hormone agonist beginning at least 4 weeks prior to the first dose of study medication\n* Histologically or cytologically confirmed diagnosis of advanced adenocarcinoma of the breast\n* Estrogen receptor positive disease\n* Human Epidermal Growth Factor Receptor 2 negative disease\n* Measurable disease per Response Evaluation Criteria in Solid Tumors v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy within the following windows:\n\n  * Tamoxifen, aromatase inhibitor, fulvestrant, or other anti-cancer endocrine therapy < 14 days;\n  * Any investigational drug therapy < 28 days or 5 half-lives (whichever is shorter)\n  * Any prior systemic chemotherapy regardless of the stop date, but the subject must have recovered to eligibility levels from prior toxicity\n* Prior treatment with CDK4/6 inhibitors\n* Unexplained symptomatic endometrial disorders (including, but not limited to, endometrial hyperplasia, dysfunctional uterine bleeding, or cysts)",
    "miscellaneous_criteria": ""
}